Product Name:
PCTK1-pY176
Product Number:
ab-pk755
Target Full Name: Cell division protein kinase 16; Protein-serine kinase PCTAIRE-1
Target Alias: CDK16; FLJ16665; KPT1; PCTAIRE; PCTAIRE protein kinase 1; PCTAIRE-motif protein kinase 1; PCTGAIRE; PCTK1; Serine/threonine-protein kinase PCTAIRE1; ENSG00000102225
Product Type Specific: PCTAIRE1 (CDK16) protein kinase phosphosite-specific antibody
Antibody Code: PK755
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y176
Protein UniProt: Q00536
Protein SigNET: PCTK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PCTK1 (PCTAIRE1, CDK16) sequence peptide Cat. No.: PE-04AJL85
Antibody Immunogen Sequence: EGT(pY)ATV(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues E173 to V179; in the protein kinase catalytic domain in subdomain I. Y176 phosphorylation is predicted to be inhibitory for phosphotransferase activity. These phosphosites are located in the kinase subdomain I region, which is involved in binding the phosphates in the ATP substrate. This is the major in vivo phosphorylation site in PCTK1 (≥336 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity of a target-sized protein by Western blotting in HeLa cells that are treated for 30 minutes with phenylarsine oxide and vanadate. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-64 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: In HeLa cells, phenylarsine oxide (PAO) increases detection of 100, 80, 75, 56, 48 and 27 kDa proteins.
Related Product 1: PCTAIRE1 (173-179) pY176 antibody blocking peptide (Cat. No.: PE-04AJL85)
Related Product 2: PCTK2 expression antibody (Cat. No.: AB-NK285-1)
Related Product 3: PCTK2 S180 phosphorylation antibody (Cat. No.: AB-PK756)
Related Product 4: PCTK3 expression antibody (Cat. No.: AB-NK286-1)
Scientific Background: PCTK1 (PCTAIRE1, CDK16) is a protein-serine/threonine kinase of the CMGC group and CDK family. It has an important role in vesicle trafficking. Specifically neuronal release of GH1 is mediated by PCTK1. It is also involved in spermatogenesis, dendrite development, neuronal differentiation, and insulin secretion. It is essential for male fertility, particularly in sperm head formation, motility, and annulus morphology. BRSK2 mediated phosphorylation of PCTK1 can be inhibited with a PCTK1 S12A mutation, which leads to fully inhibited effect on insulin secretion. It is activated primarily by binding to Cyclin Y (CCNY), which targets the kinase to the plasma membrane, a process regulated by 14-3-3 proteins. The interaction of PCTK1 and CCNY can be inhibited with a Ser-119 phosphorylation, and PCTK1 phosphotransferase activity can be constitutively activated through the mutation S153A. Its interaction with CCNY can be inhibited with a S153D mutation. PCTK1 has a central kinase domain flanked by unique N- and C-terminal extensions. Phosphorylation at Ser-119 induces interaction with 14-3-3 gamma and 14-3-3 zeta. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis. PCTK1 is frequently overexpressed in various cancers—including prostate, breast, ovarian, and cutaneous squamous cell carcinoma—where it acts as an oncogene. It aids tumor progression by phosphorylating and degrading the tumor suppressor p27, promoting cell cycle progression. This description may include information annotated by UniProt and/or Google AI.